Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888134 · ClinicalTrials.gov registry record · Phase 2
Selumetinib in Cancers With BRAF Mutations
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00888134: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00888134 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00888134, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if selumetinib is safe and effective in treating patients with cancers with a mutated BRAF gene. Selumetinib is an investigational drug that works by blocking a protein called MEK, which is known to play a role in the growth of cancer cells lines and tumors that have a mutated BRAF gene. There are multiple types of cancers that have mutations in the BRAF gene and depend on the activity of this gene for their growth and survival.
Interventions
- DRUG Selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888134
The ClinicalTrials.gov registry entry for NCT00888134 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selumetinib is the first listed.
NCT00888134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00888134 about?
NCT00888134 is a clinical study titled "Selumetinib in Cancers With BRAF Mutations". The purpose of this research study is to determine if selumetinib is safe and effective in treating patients with cancers with a mutated BRAF gene. Selumetinib is an investigational drug that works by blocking a protein called MEK, which is known to play a role in the growth of cancer cells lines an...
What is the current status of trial NCT00888134?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00888134?
The interventions under investigation include: Selumetinib (DRUG).
Who is sponsoring clinical trial NCT00888134?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.